Raved a 65-year-old fan: 'I tried this lotion on one arm and did a comparison. OMG! The difference was astounding and immediate.'
On the evening of Wednesday, April 3, about 20 Kaslo residents gathered for an open house on the Kaslo FireSmart Program and the Kaslo & Area D Community Wildfire Resiliency Plan (CWRP). Presenters included Jessie Lay, Kaslo’s FireSmart coordinator, John Cathro and Mark Elder, professional foresters, and Jeff Reyden, co-manager of the Kaslo & District Community Forest Society. Representatives from the Kaslo Volunteer Fire Department attended, including new fire chief, Eric Graham. Grace Kyle, BC
Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.